Liposomal clarithromycin delivery for the treatment of pseudomonal lung infection in cystic fibrosis.

The pulmonary infection with Pseudomonas aeruginosa is considered as one of the main causes of health deterioration in cystic fibrosis patients (CF). Efficient management of P. aeruginosa in CF remains difficult mainly with the emergence of multidrug-resistant strains leading ultimately to death. There is a pressing need for new approaches to control these Pseudomonal infections. Current studies on the antimicrobial efficacy of liposomal antibiotics have shown conflicting results. We sought to assess whether the incorporation of clarithromycin into liposomes could improve its antibacterial activity against clinical isolate of Pseudomonas aeruginosa from CF patients. Different formulations of liposomal clarithromycin were prepared, characterized and their antibacterial activities against resistant strains of P. aeruginosa were investigated. These formulations reduced the biofilm formation, the virulence factors production and the bacterial motilities compared to free drug. The therapeutic importance of liposome containing macrolides in the management of experimental pseudomonal lung infection in animals is warranted.

Name thesis:degree_name

Master of Science in Biology

Grantor dc:publisher

Laurentian University of Sudbury

Year dc:date.issued

2013

Author dc:creator

• Alhajlan, Mai Mohsen A.

• Cystic fibrosis
• Liposomes
• Macrolides
• Pseudomonas aeruginosa
• Virulence factors

Language dc:language.iso

en

Repository record dc:identifier.uri

https://laurentian.scholaris.ca/handle/10219/2119

OAI record oai:identifier

https://laurentian.scholaris.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Alaurentian.scholaris.ca%3A10219%2F2119